SELLAS Life Sciences Group (NASDAQ:SLS) Sees Large Volume Increase – Still a Buy?

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) saw an uptick in trading volume on Tuesday . Approximately 6,253,825 shares were traded during mid-day trading, a decline of 25% from the previous session’s volume of 8,341,135 shares.The stock last traded at $14.1320 and had previously closed at $15.45.

Analysts Set New Price Targets

Several research firms have recently weighed in on SLS. Maxim Group boosted their target price on SELLAS Life Sciences Group from $7.00 to $10.00 and gave the company a “buy” rating in a research report on Thursday, March 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research note on Tuesday, April 21st. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, SELLAS Life Sciences Group has a consensus rating of “Hold” and a consensus price target of $10.00.

SELLAS Life Sciences Group Stock Performance

The firm has a market capitalization of $2.88 billion, a P/E ratio of -63.43 and a beta of 2.50. The stock’s 50 day simple moving average is $7.35 and its 200 day simple moving average is $5.27.

SELLAS Life Sciences Group (NASDAQ:SLS) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. California State Teachers Retirement System raised its stake in SELLAS Life Sciences Group by 22.4% in the first quarter. California State Teachers Retirement System now owns 9,337 shares of the company’s stock worth $39,000 after buying an additional 1,709 shares in the last quarter. Grange Capital LLC lifted its stake in shares of SELLAS Life Sciences Group by 18.5% during the 4th quarter. Grange Capital LLC now owns 16,001 shares of the company’s stock worth $60,000 after purchasing an additional 2,500 shares during the last quarter. Invesco Ltd. boosted its position in SELLAS Life Sciences Group by 6.2% during the fourth quarter. Invesco Ltd. now owns 53,293 shares of the company’s stock valued at $201,000 after purchasing an additional 3,114 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in SELLAS Life Sciences Group by 13.6% in the fourth quarter. The Manufacturers Life Insurance Company now owns 38,018 shares of the company’s stock valued at $143,000 after purchasing an additional 4,564 shares during the last quarter. Finally, Equitable Holdings Inc. lifted its position in shares of SELLAS Life Sciences Group by 18.5% during the fourth quarter. Equitable Holdings Inc. now owns 32,060 shares of the company’s stock valued at $121,000 after buying an additional 5,000 shares during the last quarter. 17.38% of the stock is currently owned by institutional investors.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.